2019 Leishmaniasis (Kala-Azar) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 99 pages | ID: 2C10FFD2F50EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Leishmaniasis (Kala-Azar) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Leishmaniasis (Kala-Azar). It presents in-depth analysis of Leishmaniasis (Kala-Azar) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Leishmaniasis (Kala-Azar).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Leishmaniasis (Kala-Azar) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Leishmaniasis (Kala-Azar)

The research work is prepared through extensive and continuous research on Leishmaniasis (Kala-Azar) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Leishmaniasis (Kala-Azar) patients are identified
• The report includes panorama of Leishmaniasis (Kala-Azar) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Leishmaniasis (Kala-Azar) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Leishmaniasis (Kala-Azar) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Leishmaniasis (Kala-Azar) Clinical Trials by Region
  2.2.2 Average Enrollment of Leishmaniasis (Kala-Azar) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Leishmaniasis (Kala-Azar) Treatment, 2019

3. REGION WISE LEISHMANIASIS (KALA-AZAR) CLINICAL TRIALS

3.1 Asia Pacific Leishmaniasis (Kala-Azar) Clinical Trials by Country
3.2 Europe Leishmaniasis (Kala-Azar) Clinical Trials by Country
3.3 North America Leishmaniasis (Kala-Azar) Clinical Trials by Country
3.4 Middle East and Africa Leishmaniasis (Kala-Azar) Clinical Trials by Country
3.5 South and Central America Leishmaniasis (Kala-Azar) Clinical Trials by Country

4. LEISHMANIASIS (KALA-AZAR) CLINICAL TRIAL TRENDS

4.1 Start Year wise Leishmaniasis (Kala-Azar) Clinical Trials
4.2 Phase wise Leishmaniasis (Kala-Azar) Clinical Trials
4.3 Trial Status wise Leishmaniasis (Kala-Azar) Clinical Trials
4.4 Trial Type wise Leishmaniasis (Kala-Azar) Clinical Trials

5. LEISHMANIASIS (KALA-AZAR) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Leishmaniasis (Kala-Azar) Trials by Year
5.2 Average Enrollment in Leishmaniasis (Kala-Azar) Trials by Phase
5.3 Average Enrollment in Leishmaniasis (Kala-Azar) Trials by Status
5.4 Average Enrollment in Leishmaniasis (Kala-Azar) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN LEISHMANIASIS (KALA-AZAR) CLINICAL TRIALS

6.1 Leishmaniasis (Kala-Azar) Trials by Sponsor Type
6.2 Leishmaniasis (Kala-Azar) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Leishmaniasis (Kala-Azar) Trials- Phase
7.2 Leishmaniasis (Kala-Azar) Trials- Phase
7.3 Leishmaniasis (Kala-Azar) Trials- Phase
7.4 Leishmaniasis (Kala-Azar) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Leishmaniasis (Kala-Azar) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Figure 7: North America – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Figure 9: Leishmaniasis (Kala-Azar) Clinical Trials by Phase
Figure 10: Leishmaniasis (Kala-Azar) Clinical Trials by Trial Status
Figure 11: Leishmaniasis (Kala-Azar) Clinical Trials by Type
Figure 12: Leishmaniasis (Kala-Azar) Clinical Trials by Sponsor Type
Figure 13: Leishmaniasis (Kala-Azar) Clinical Trials by Leading Sponsors
Figure 14: Leishmaniasis (Kala-Azar) Average Enrollment by Phase
Figure 15: Leishmaniasis (Kala-Azar) Average Enrollment by Trial Status
Figure 16: Leishmaniasis (Kala-Azar) Average Enrollment by Type
Figure 17: Leishmaniasis (Kala-Azar)- Average Enrolment by Type of Sponsors
Figure 18: Leishmaniasis (Kala-Azar)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Leishmaniasis (Kala-Azar) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Table 5: Europe – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Table 7: North America – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Leishmaniasis (Kala-Azar) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Leishmaniasis (Kala-Azar) Average Enrollment by Phase
Table 15: Leishmaniasis (Kala-Azar) Average Enrollment by Trial Status
Table 16: Leishmaniasis (Kala-Azar) Average Enrollment by Type
Table 17: Leishmaniasis (Kala-Azar)- Average Enrolment by Type of Sponsors
Table 18: Leishmaniasis (Kala-Azar)- Enrolment by Leading Sponsors